Identify & Eliminate Waste, Stabilize & Streamline Operations, & Design Flexible, Modular, & Standardized Processes to Increase Quality while Decreasing Cost of Cell & Gene Therapies

Welcome to the LEAN Cell & Gene Boston Summit
First of the LEAN Cell & Gene Event Series!

Manufacturing Advanced Therapies Just-In-Time for All Patients

Despite tremendous scientific progress, stunning clinical results, and a slew of commercial approvals, this paradigm shifting industry finds itself facing an increasingly oppressive macro-economic climate.

Public and private investment in CGT is trending downwards to decade lows. Pipelines and workforces are being slashed at increasing rates. Input costs are expected to rise as world leaders erect trade barriers and protectionist policies putting more pressure on supply chains and balance sheets.

Strategically taking place one day before the flagship 10th CAR-TCR summit, the first of this event series aims to usher in a renaissance for CGT developers and manufacturers by helping you (re)discover LEAN concepts, knowledge, practices, and methods for how to systematically identify and eliminate waste, build a culture of continuous improvement, and drive operational excellency no matter where in the development cycle you are, so that we can deliver advanced therapies just-in-time to all patients.

World-Class Speaker Faculty:

Ignacio Nunez, Chief Operations Officer, Cell Ready - Lean Cell & Gene Boston Summit

Ignacio Nunez

Chief Operations Officer

Cell Ready LLC

Mamta Kalra - Lean Cell & Gene Boston Summit

Mamta Kalra

Vice President CMC

Immatics N.V.

Adam Beebe - Lean Cell & Gene Boston Summit

Adam Beebe

Manager GMP Cell Production

Seattle Children’s Therapeutics

Steven Feldman - Lean Cell & Gene Boston Summit

Steve Feldman

Site Head and Scientific Director

Stanford University

Fred Parietti, Chief Executive Officer, Multiply Labs - LEAN Cell & Gene Boston Summit

Fred Parietti

Chief Executive Officer

Multiply Labs

Matt Hewitt - Lean Cell & Gene Boston Summit

Matt Hewitt

Vice President Chief Technology Officer Manufacturing Business Division

Charles River Laboratories

Attend this Meeting to:

Hear from LEAN Cell & Gene Leaders

Learn how LEAN principles are being successfully applied in CGT to reduce manufacturing overhead, shorten development timelines, and improve cost-efficiency across the product lifecycle

Stabilize Operations

Hear from leading academic, clinical, and commercial CGT institutions on practical ways to stabilize operations and do more with less

Logarithmically Increase Throughput

Explore how a G-Rex production system enables higher throughput through parallel processing, shorter cycle times, and single-piece (continuous) flow

Structurally Reduce Cost

Review how operational excellency and continuous improvement can lead to structurally reduced cost through the systematic identification and elimination of waste

Achieve Total Patient Access

Connect with peers and industry leaders during sessions and networking opportunities to exchange ideas on how we can deliver quality drug product just-in-time to the total addressable patient population

As cell therapies continue to demonstrate transformative potential in the clinic whilst reaching new milestones for commercial success, the 10th CAR-TCR Summit is returning as the worlds leading global forum to accelerate end-to-end development of cell therapies to patients in need.

Built by industry for industry, the CAR-TCR summit features end-to-end coverage of every stage of cell therapy development. From breakthroughs in novel engineering and armoring technologiesstreamlined manufacturing to meet tight timelines, optimizing pre-clinical models to reviewing clinical data, to efficiently characterizing your cell therapy product.

ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.

The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs.

CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.